Evidence map›Paper›PMID 36975415›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Dan Li, Shenglan Huang, Chen Luo, Yongkang Xu, Shumin Fu, Kan Liu, Jianbing Wu

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dan LiDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Shenglan HuangDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Chen LuoDepartment of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Yongkang XuDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Shumin FuDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.ORCID 0000-0002-1854-9267
Kan LiuDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Jianbing WuDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Nanchang University · CN

Funding

Project of the Jiangxi Provincial Department of Science and Technology 20202BAB206052the National Natural Science Foundation of China 82060435the Project of the Jiangxi Provincial Innovation Fund for Graduate Students YC2021-B041
6 · The paper itself

Abstract

The Chemokine-like factor (

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAlgorithmsBiomarkersChemokinesHumansMARVEL Domain-Containing ProteinsPrognosisTumor MicroenvironmentBiomarkersChemokinesCKLF protein, humanCMTM4 protein, humanCMTM5 protein, humanCMTM7 protein, humanCMTM8 protein, humanMARVEL Domain-Containing ProteinsCMTM family memberhepatocellular carcinomaimmune infiltrationprognosissurvival

Identifiers

PMID36975415
PMCPMC10047849
OpenAlexW4321596426

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read12
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.